Active-ingredient Dossier
Methotrexate
Active-ingredient Dossier for Methotrexate (antimetabolite antifolate). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: CHEXATE
- Brand: METHOBLASTIN
- Brand: METHOTREXATE EBEWE
- Brand: Pfizer
- Brand: TREXJECT
- Brand: ARX-METHOTREXATE
- Therapeutic area: Oncology
- Therapeutic area: Immunology
What is
Methotrexate Methotrexate is an antimetabolite antifolate.
Australian brands containing
Methotrexate — METHOTREXATE EBEWE — TREXJECT — ARX-METHOTREXATE — METHOTREXATE — IMUTREX — METHOTREXATE ADVZ — METHOTREXATE CIPLA — Methotrexate Injection
Therapeutic areas
Methotrexate is registered in oncology (5 brands), immunology (3 brands), and complementary medicine (3 brands).
Sponsor landscape
Methotrexate is marketed by seven sponsors: Cipla, Boucher & Muir, Hospira, Accord Healthcare, Sandoz, and Pfizer (Perth).
PBS and regulatory activity
Two brands containing methotrexate have PBS-listed items, with the latest PBS schedule date of 1 May 2026. Two brands have PBAC outcomes on record, with the latest PBAC decision dated 1 July 2024.